Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

Slides:



Advertisements
Similar presentations
©American Society of Clinical Oncology All rights reserved - American.
Advertisements

Breast Cancer and Bone Health. Bone Homeostasis Bone is a living tissue which is constantly renewing via a balance of resorption of old bone (via Osteoclasts)
Osteoporosis Osteoporosis is defined as a loss of bone mass or bone mineral density characterized by height reduction, fractures, back/neck pain, and stooped.
Treatment. Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men.
Osteoporosis. Introduction Osteoporosis is “a disease of the bones that happens when you lose too much bone, make too little bone, or both.” - National.
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,
Oral Bisphosphonate and Breast Cancer: Prospective Results from the Women’s Health Initiative (WHI) Chlebowski RT et al. SABCS 2009; Abstract 21.
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
Endpoint Comparison for Osteoporosis Assessment in Cancer Control Studies (N02C1 and N03CC) A. C. Dueck 1, P. J. Atherton 2, H. Liu 2, S. L. Hines 3, C.
Extended Treatment Effects with Zoledronic Acid Based on Poster 1070 “The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment in Osteoporosis: a Randomized.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Start or Switch?: Latest data from ABCSG/ARNO
Published online July 24, Aromatase inhibitors versus tamoxifen in early breast.
Osteoporosis Armed Forces Academy of Medical Sciences.
Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials The Lancet Volume 386, Issue.
MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.
Osteoclast Inhibitors in Malignancy
The silent risk of bone loss How should we manage patients?
San Antonio Breast Cancer Symposium. December
Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis  Peyman Hadji  Critical Reviews in Oncology.
Mostafa AL Turk Tatiana Hawat
Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer
Finding the Right Fit: Personalizing Treatment in Metastatic Castration-Resistant Prostate Cancer.
Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Goal-directed Treatment for Osteoporosis
New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.
Endocrine Combinations in HR-Positive MBC: The Future Is Now
Health Science 1 Project
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
The Future of Osteoporosis: Improving Care Along the Way
Updates and Insights on the Medical Science of Prostate Cancer
Neoadjuvant Therapy for HER2-Positive Breast Cancer
Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting
The Challenge of Bone-Metastatic PC
Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update
سرطان الثدي Breast Cancer
Overall Program Goals. Overall Program Goals Current Approaches.
Cancer Stem Cell Therapies in Gastrointestinal Cancers
PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update
Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer.
New Treatments for CTEPH
PARP Inhibitors and Cancer: What Do You Need to Know?
CDK4/6 Inhibitors in Breast Cancer:
Managing gBRCA-Positive Metastatic Breast Cancer
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients Breast Care 2016;11: DOI: / Fig. 1. Strategies.
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
Treatment of HR+ Breast Cancer: A Clinical Update
A Better Solution For Cancer Patients With VTE?
VTE in Cancer.
Inquiry into geographical inequalities in breast cancer
The Road to Quality Improvement in HER2-Positive Breast Cancer
The Role of IDH Inhibitors in Hematologic Malignancies
Yong-jiang Hei  European Urology Supplements 
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
Menopause. Menopause Health screening of healthy postmenopausal women.
Volume 386, Issue 10001, Pages (October 2015)
Badwe RA et al. SABCS 2009;Abstract 72.
Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.
Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid  Theresa A. Guise,
Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer
The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients  Kurt Miller  European Urology Supplements  Volume.
PAH Pathways: What Do the Data Tell Us?”
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
My PAH Patient.
Revisión bibliográfica 4º trimestre de 2017
Subjects Randomized to Denosumab or Bisphosphonate Therapy
Presentation transcript:

Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

Cancer-Treatment-Induced Bone Loss (CTIBL)

Clodronate and Bone Mineral Density (Hip)

Bone Mineral Density Substudy --ABCSG-12: Effect of Zoledronic Acid Percent Change, Lumbar Spine

Denosumab for CTIBL (Lumbar Spine)

Metastatic Niches in Bone Marrow

Differential Impact of Menopausal Status

The "Low Estrogen" Hypothesis

Adjuvant Bisphosphonate Treatment Breast Cancer Recurrence-Postmenopause*

Conclusions: EBCTCG Meta-Analysis

ABCSG-12 Trial Design

Adjuvant Denosumab in Breast Cancer (ABCSG-18, Phase 3) Primary Endpoint, First Clinical Fracture

Adjuvant Denosumab in Breast Cancer (ABCSG-18 Subgroup) Tumor Size > 2 cm

Bone-Targeting Therapy in Adjuvant Breast Cancer Setting Clinical Conclusions

References

References (cont)

References (cont)

Abbreviations

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.